June 26, 2025 — Fujifilm VisualSonics Inc., a provider of ultra-high frequency ultrasound and photoacoustic imaging systems, has announced the availability of the multi-modal Vevo F2 LAZR-X20 Photoacoustic Imaging Platform. The system features high-powered, intelligent laser technology for advanced tissue characterization with high anatomical accuracy for preclinical animal models.
“For more than two decades, Fujifilm VisualSonics has been delivering ultra-high frequency ultrasound and photoacoustic imaging solutions to the scientific research community,” said Greg Nesbitt, vice president, global high frequency, Fujifilm VisualSonics Inc. “As a leader in the space, we saw an opportunity to expand the scope of questions that can be answered using photoacoustics. The Vevo LAZR-X20 underscores our commitment to constantly innovating and bringing more applications and capabilities to a broader set of research domains.”
The advanced laser technology in the Vevo F2 LAZR-X20 provides enhanced imaging depth and high-resolution in real time, allowing researchers to visualize and measure various tissue types and contrast agents. Leveraging a unique wavelength range of 660-1320 nm, the system unlocks advanced tissue characterization capabilities that were beyond reach with our previous-generation technologies. Tissue chromophores like lipids and collagen, which exhibit unique absorption profiles within this range, can be detected non-invasively. This enables researchers to visualize tumor microenvironments and opens the potential for quantifying therapeutic efficiency. This paves the way for possible deeper insights and more impactful discoveries.
“This cutting-edge product represents a significant advancement in our portfolio, seamlessly integrating photoacoustics with ultrasound imaging into a single platform,” said Andrew Needles, director, product innovation, Fujifilm VisualSonics Inc. “The new system provides excellent image quality and an expanded spectral range, providing researchers with comprehensive data for their imaging studies. We believe this breakthrough technology will not only enhance current research capabilities but also has the potential to unlock new applications, particularly in the fields of oncology and neurobiology.”
Learn more about the multi-modal Vevo F2 LAZR-X20 here.
For more information, please go to: www.visualsonics.com.
September 29, 2026 
